Moderna expands collaboration with OpenAI to boost mRNA therapeutics
Moderna will embed OpenAI’s generative AI tools throughout its organisation and adopt ChatGPT Enterprise to use Generative AI…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
25 Apr 24
Moderna will embed OpenAI’s generative AI tools throughout its organisation and adopt ChatGPT Enterprise to use Generative AI…
25 Apr 24
The sBLA submission is supported by data from Part 1 of RUBY Phase 3 trial which successfully met…
25 Apr 24
The approval was based on results from three controlled clinical trials of females aged 18 and above in…
25 Apr 24
The approval was based on the results from the Phase 3 PROTECT study which reached its primary endpoint…
25 Apr 24
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAseq xHYB Mycobacterium tuberculosis Panel…
24 Apr 24
The competing lawsuits over Covid-19 vaccines are a part of the ongoing litigation worldwide, centred around mRNA technology,…
24 Apr 24
The deal includes EP262, a first-in-class, potent, highly selective, once-daily small molecule MRGPRX2 antagonist, and EP547, a first-in-class…
24 Apr 24
The approval was based on the results from the Phase 3 EMBARK trial which met its primary endpoint…
24 Apr 24
The approval is based on results from the ALPHA Phase 3 trial in which Voydeya met the primary…
24 Apr 24
AIRS Medical Inc., a leading provider of AI-powered healthcare solutions, recently announced that it has signed supply contracts…